Clinical and immunological features of psoriasis in the post-COVID period

Pechatnikova E.A.; Udzhukhu V.Yu.; Artemyeva S.I.; Kubylinskiy A.A.

doi:https://doi.org/10.17116/klinderma202322041412

Pechatnikova E.A.

The Russian National Research Medical University named after N.I. Pirogov

ORCID: 0000-0002-4097-4884

Udzhukhu V.Yu.

The Russian National Research Medical University named after N.I. Pirogov

ORCID: 0000-0002-3351-9138

Artemyeva S.I.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology

SPIN RSCI: 2627-9842
Scopus AuthorID: 57216937447
ORCID: 0000-0002-2793-8862

Kubylinskiy A.A.

The Russian National Research Medical University named after N.I. Pirogov

ORCID: 0000-0002-4645-8215

Clinical and immunological features of psoriasis in the post-COVID period

Authors:

Pechatnikova E.A., Udzhukhu V.Yu., Artemyeva S.I., Kubylinskiy A.A.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2023;22(4): 412‑417

DOI: 10.17116/klinderma202322041412

Read: 1599 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Pechatnikova EA, Udzhukhu VYu, Artemyeva SI, Kubylinskiy AA. Clinical and immunological features of psoriasis in the post-COVID period. Russian Journal of Clinical Dermatology and Venereology. 2023;22(4):412‑417. (In Russ.)
https://doi.org/10.17116/klinderma202322041412

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

Close metadata

Abstract:

BACKGROUND

Immune dysregulation that occurs with coronavirus infection leads to increased resistance of the psoriatic process to routine treatment methods and warrants the study of the features of the clinical course and immunogenesis of psoriasis in patients after COVID-19.

OBJECTIVE

To develop clinical and immunological criteria for the post-COVID course of psoriasis and identify clinical and pathogenetic variants of this dermatosis, considering their most pathognomonic diagnostic signs.

MATERIAL AND METHODS

The study included 125 patients with psoriasis who had COVID-19 during the last year. Testing was conducted using the «Dermatological Quality of Life Index» questionnaire. The cytokine profile, serum/plasma adhesion molecule levels, lytic activity of natural killer cells, endogenous nitric oxide level, and TLR2 and TLR4 expression on peripheral blood monocytes were measured.

RESULTS

According to immunological studies, there are three types of psoriasis characterized by diverse, partly multidirectional immune disorders. Analysis of the results of clinical and immunological studies showed that in type 1, the characteristic clinical manifestations of the disease include psoriasis vulgaris with moderate and severe course, exudative and arthropathic psoriasis. Type 2 includes psoriasis vulgaris of various severity; arthropathic psoriasis and other types are less common. In type 3, clinical manifestations of other psoriasis types and psoriatic onychodystrophy were more often observed.

CONCLUSION

In patients with psoriasis after COVID-19, various immune disorders were observed. The identified clinical and immunological features of the psoriasis course in the post-COVID period will contribute to a more rational and targeted approach to treatment regimens.

Keywords:

psoriasis

post-COVID

clinical and pathogenetic variants

clinical and immunological

TNF-α

IFN-γ

endogenous NO

Authors:

Pechatnikova E.A.

The Russian National Research Medical University named after N.I. Pirogov

ORCID: 0000-0002-4097-4884

Udzhukhu V.Yu.

The Russian National Research Medical University named after N.I. Pirogov

ORCID: 0000-0002-3351-9138

Artemyeva S.I.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology

SPIN RSCI: 2627-9842
Scopus AuthorID: 57216937447
ORCID: 0000-0002-2793-8862

Kubylinskiy A.A.

The Russian National Research Medical University named after N.I. Pirogov

ORCID: 0000-0002-4645-8215

Received:

19.10.2022

Accepted:

19.05.2023

Close metadata

References:

Kungurov NV, Kohan MM, Syrneva TA, Shakirova AN, Kuznecov ID. Features and trends in the incidence and prevalence of psoriasis in the subjects of the Russian Federation for the period 2009–2017. International journal of applied and fundamental research. 2021;8:9-15. (In Russ). https://doi.org/10.17513/mjpfi.13255
Zhukova OV, Kasihina EI. Epidemiological aspects of psoriasis in children. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2018;17(5):24-29. (In Russ). https://doi.org/10.17116/klinderma201817051
Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015;64:66-73. https://doi.org/10.1016/j.jaut.2015.07.008
Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol. 2005;5(9):699-711. https://doi.org/10.1038/nri1689
Zhang Z, Wan X, Huang B, Chen Y, Zhang Y. Yang L, Liu S, Liu J, COVID19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):128. https://doi.org/10.1038/s41392-020-00243-2
Immunological parameters in patients with psoriasis, depending on the severity of the disease. Barilo AA, Smirnova SV. Russian Journal of Immunology, 2019;13(2-1):147-149. (In Russ.).
Tokuyama M, Mabuchi T. New Treatment Addressing the Pathogenesis of Psoriasis. Int J Mol Sci. 2020;21(20):7488. https://doi.org/10.3390/ijms21207488
Hou Y, Zhu L, Tian H, Sun HX, Wang R, Zhang L, Zhao Y. IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis. Protein Cell. 2018;9(12):1027-1038. https://doi.org/10.1007/s13238-018-0505-z
Cytokines in psoriasis. Alcantara CC, Reiche EMV, Simão ANC. Adv Clin Chem. 2021;100:171-204. https://doi.org/10.1016/bs.acc.2020.04.004
Ogawa E, Sato Y, Minagawa A, Okuyama R.Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018;45(3):264-272. https://doi.org/10.1111/1346-8138.14139
Svechnikova EV, Marshani ZB, Fomin KA, Evdokimov EYU. A new coronavirus infection in the aspect of psoriasis. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2021;20(3):77-84. (In Russ). https://doi.org/10.17116/klinderma20212003177
Behrangi E, Sadeghzadeh-Bazargan A, Salimi N, Shaka Z, Feyz Kazemi MH, Goodarzi A. Erythrodermic flare-up of psoriasis with COVID-19 infection: A report of two cases and a comprehensive review of literature focusing on the mutual effect of psoriasis and COVID-19 on each other along with the special challenges of the pandemic. Clin Case Rep. 2022;10(4): e05722. https://doi.org/10.1002/ccr3.5722
Mohamed Khosroshahi L, Rokni M, Mokhtari T, Noorbakhsh F. Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview. Int Immunopharmacol. 2021;93:107364. https://doi.org/10.1016/j.intimp.2020.107364
Interleukin-1 in COVID-19 Infection: Immunopathogenesis and Possible Therapeutic Perspective. Mardi A, Meidaninikjeh S, Nikfarjam S, Majidi Zolbanin N, Jafari R. Viral Immunol. 2021;34(10):679-688. https://doi.org/10.1089/vim.2021.0071
Zaxarov VV. Post-covid syndrome from the point of view of a neurologist. Behavioral Neurology. 2021;2:14-22. (In Russ). https://doi.org/10.46393/2712-9675_2021_2_14_22